National Graphite Corp. is an exploration company, which engages in the exploration of gold, silver, and related minerals. The company is headquartered in Dusseldorf, Nordrhein-Westfalen. The company went IPO on 2009-06-30. The firm is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The firm operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.
NGRC stock price ended at $0.04 on 星期二, after rising 0.00%
On the latest trading day Jan 13, 2026, the stock price of NGRC rose by 0.00%, climbing from $0.03 to $0.04. Throughout the session, the stock experienced a volatility of 33.33%, with prices fluctuating between a daily low of $0.03 and a high of $0.04. Alongside this price increase, trading volume also rose by 11.6K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 29.8K shares were traded, amounting to a market value of approximately $6.1M.